Cellares and Technology Partner Intend to Boost Cell Q's Functionality for Industrial-Scale Quality Control in Cell Therapy
In the rapidly evolving field of cell therapy manufacturing, Cellares is set to make a significant stride with the introduction of their innovative Quality Control (QC) platform, Cell Q. This modular and highly configurable system promises to reduce labor dependency, minimize batch failure risk, and enable global scaleup for commercial developers.
On Thursday, September 25, John Cesarek, Cellares' senior director of automation, will present "From Bottlenecks to Breakthroughs: Automating Commercial-Scale QC Testing with Cell Q" at the 10th Annual CAR-TCR Summit at 2:15 PM ET. The presentation is expected to delve into the transformative potential of Cell Q, showcasing its capabilities in automating and streamlining labor-intensive, error-prone in-process and release assays.
At the heart of Cell Q lies its ability to streamline high-throughput sample preparation, real-time data tracking, and reporting. The platform is purpose-built to advance cell therapy manufacturing, offering a ready-made infrastructure to support GMP compliance, digital traceability, and audit-readiness from day one. This infrastructure is designed to de-risk tech transfer and accelerate IND timelines for early-stage developers.
Cytek Biosciences and Advanced Instruments are among the technology providers that have optimized their solutions to work seamlessly with the Cell Q platform. Cytek Biosciences has optimized fully automated full spectrum flow cytometry workflows, from plate mapping through takedown, while Advanced Instruments has integrated and automated verification of liquid handling, performance, and calibration with its Artel portfolio on the Cell Q platform.
Slingshot Biosciences and AltemisLab are also partnering with Cellares to further enhance the capabilities of the Cell Q platform. Slingshot Biosciences has developed cell mimics and ready-to-use flow cytometry panels, enabling reproducible results across sites, operators, and instruments on the Cell Q platform. AltemisLab, on the other hand, has integrated pre-barcoded cryovials, tube decapping, and automated thawing on the Cell Q platform to preserve Chain of Identity (COI) and Chain of Custody (COC) across the QC lifecycle.
Tecan, another technology partner, has delivered advanced liquid handling systems and hardware-software interfaces to enable scalable, reproducible workflows and results on the Cell Q platform. These strategic partnerships aim to streamline all critical QC testing operations, ensuring the Cell Q platform can support automated QC release testing of up to 6,000 cell therapy batches per year.
Fabian Gerlinghaus, CEO and co-founder of Cellares, claims that the Cell Q platform is the first of its kind in the industry. The platform was built to match the commercial manufacturing throughput of the Cell Shuttle, with fewer handoffs, less failure, and better data quality. Traditional manual QC infrastructure is expected to struggle to keep pace with the Cell Q platform.
At the 10th Annual CAR-TCR Summit, Cellares will present drug product release data automatically generated on the Cell Q and case studies highlighting its automation capabilities. The event promises to be a significant milestone in the cell therapy industry, as Cellares unveils the potential of the Cell Q platform to revolutionize QC testing and pave the way for a more efficient, scalable, and reliable cell therapy manufacturing process.
